Vertex Pharmaceuticals Incorporated (VRTX) Gross Margin: 86.28%
Is Vertex Pharmaceuticals Incorporated’s gross margin high or low?
Vertex Pharmaceuticals Incorporated's gross margin of 86.28% is in line with its 5-year average of 87.08%, around the middle of its 5-year range (85.03%–88.14%).
The gross margin for Vertex Pharmaceuticals Incorporated (VRTX) is 86.28% as of Wednesday, June 10, 2026. It is above its 12-month average by 0.83% (85.57%).
VRTX Gross Margin Chart
VRTX Average Gross Margin Chart
VRTX Current vs Average Gross Margin Chart
VRTX Gross Margin Metrics
GROSS MARGIN
86.28%
GROSS MARGIN AVG TTM
85.57%
GROSS MARGIN AVG 3Y
86.56%
GROSS MARGIN AVG 5Y
87.08%
GROSS MARGIN AVG 10Y
87.30%
GROSS MARGIN AVG 15Y
87.88%
GROSS MARGIN AVG 20Y
88.78%
CURRENT VS TTM AVG
+0.83%
CURRENT VS 3Y AVG
-0.33%
CURRENT VS 5Y AVG
-0.91%
CURRENT VS 10Y AVG
-1.17%
CURRENT VS 15Y AVG
-1.82%
CURRENT VS 20Y AVG
-2.81%
VRTX Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated (VRTX) | — | 86.28% | 85.57% | 86.56% | 87.08% |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 68.75% | 62.23% | 59.55% | 57.82% |
| Medtronic plc (MDT) | $103.04B | 65.02% | 65.17% | 65.34% | 65.75% |
| CVS Health Corporation (CVS) | $125.16B | 13.87% | 13.78% | 14.92% | 15.96% |
| Danaher Corporation (DHR) | $130.25B | 60.68% | 60.22% | 59.98% | 59.48% |
| Elevance Health Inc. (ELV) | $87.43B | 23.16% | 26.70% | 26.59% | 26.68% |
| Cigna Corporation (CI) | $78.25B | 9.30% | 9.98% | 11.47% | 12.36% |
| Pfizer Inc. (PFE) | $146.36B | 69.35% | 68.05% | 62.23% | 63.06% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 66.29% | 66.73% | 66.82% | 67.04% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 79.35% | 78.55% | 78.10% | 78.28% |
Gross Margin Analysis
Gross Margin
86.3%
(Revenue - COGS) / Revenue
Vertex Pharmaceuticals Incorporated Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Vertex Pharmaceuticals Incorporated Gross Margin FAQ
- What is the gross margin for Vertex Pharmaceuticals Incorporated (VRTX)?
- The gross margin for VRTX stock is 86.28%.
- Is Vertex Pharmaceuticals Incorporated's gross margin high or low?
- Vertex Pharmaceuticals Incorporated's gross margin of 86.28% is in line with its 5-year average of 87.08%, around the middle of its 5-year range (85.03%–88.14%).
- What is the TTM average gross margin for Vertex Pharmaceuticals Incorporated (VRTX)?
- The TTM average gross margin for VRTX stock is 85.57%.
- What is the 3Y average gross margin for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 3Y average gross margin for VRTX stock is 86.56%.
- What is the 5Y average gross margin for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 5Y average gross margin for VRTX stock is 87.08%.
- What is the 10Y average gross margin for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 10Y average gross margin for VRTX stock is 87.30%.
- What is the 15Y average gross margin for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 15Y average gross margin for VRTX stock is 87.88%.
- What is the 20Y average gross margin for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 20Y average gross margin for VRTX stock is 88.78%.
Vertex Pharmaceuticals Incorporated Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 85.03% |
| 2024-12-31 | 86.11% |
| 2023-12-31 | 87.21% |
| 2022-12-31 | 87.90% |
| 2021-12-31 | 88.06% |
| 2020-12-31 | 88.14% |
| 2019-12-31 | 86.84% |
| 2018-12-31 | 86.56% |
| 2017-12-31 | 88.95% |
| 2016-12-31 | 87.64% |
| 2015-12-31 | 87.84% |
| 2014-12-31 | 89.49% |
| 2013-12-31 | 89.25% |
| 2012-12-31 | 81.67% |
| 2011-12-31 | 94.29% |
| 2010-12-31 | 91.12% |
| 2009-12-31 | 86.08% |
| 2008-12-31 | 91.06% |
| 2007-12-31 | 93.01% |
| 2006-12-31 | 94.38% |
| 2005-12-31 | 93.72% |
| 2004-12-31 | 94.50% |
| 2003-12-31 | 95.48% |
| 2002-12-31 | 82.44% |
| 2001-12-31 | 76.34% |
| 2000-12-31 | 94.78% |
| 1999-12-31 | 105.52% |
| 1998-12-31 | 110.14% |
| 1997-12-31 | 108.22% |
| 1996-12-31 | 124.06% |
Related Metrics
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani